Drug intelligence / Profile preview

AQX-1000

Development stage: Preclinical
Lead developer: Neurogene
Modality: Small Molecules
Administration: Oral

Overview

AQX-1000 is a series of small molecule modulators of Src homology 2 domain-containing inositol 5-phosphatase 1 (SHIP1) developed by Aquinox Pharmaceuticals. SHIP1 is a signaling enzyme primarily expressed in hematopoietic cells that acts as a negative regulator of the PI3K/Akt pathway by converting PI(3,4,5)P3 to PI(3,4)P2. The AQX-1000 program was designed to leverage this mechanism for the treatment of inflammatory diseases and hematologic malignancies. While Aquinox's lead candidate, rosiptor (AQX-1125), was a SHIP1 activator, the AQX-1000 series represented next-generation compounds within their preclinical pipeline intended to address a broader range of indications including heme malignancies.

Targets

SHIP1 (SH2-containing inositol 5-phosphatase 1)

Beyond the preview

Go deeper on AQX-1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AQX-1000.

Explore the full profile